SomaLogic, a Boulder, Colorado-based biomarker discovery and clinical diagnostics company, is expected to go public via a merger with a special purpose acquisition company (SPAC). We'll update this page as new information becomes available.
Our top pick for
Beginners
Our top pick for
Building a portfolio
Our top pick for
Advanced traders
| Latest market close | $4.48 |
|---|---|
| 52-week range | $4.20 - $14.72 |
| 50-day moving average | $5.70 |
| 200-day moving average | $9.17 |
| Wall St. target price | $12.25 |
| PE ratio | N/A |
| Dividend yield | $0 (0%) |
| Earnings per share (TTM) | $-0.53 |
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Historical closes compared with the close of $4.48 from 2022-07-01
| 1 week (2022-06-28) | -9.86% |
|---|---|
| 1 month (2022-06-06) | -22.09% |
| 3 months (2022-04-06) | -37.69% |
| 6 months (2022-01-06) | -58.36% |
| 1 year (2021-07-02) | -64.23% |
|---|---|
| 2 years (2020-07-02) | N/A |
| 3 years (2019-07-02) | N/A |
| 5 years (2017-07-02) | N/A |
| Revenue TTM | $85.7 million |
|---|---|
| Gross profit TTM | $11.1 million |
| Return on assets TTM | -12.06% |
| Return on equity TTM | -20.57% |
| Profit margin | -95.68% |
| Book value | $3.39 |
| Market capitalisation | $853.1 million |
TTM: trailing 12 months
We're not expecting Somalogic to pay a dividend over the next 12 months.
You may also wish to consider:
SomaLogic, Inc. operates as a protein biomarker discovery and clinical diagnostics company in the United States. It develops slow off-rate modified aptamers (SOMAmers), which are modified nucleic acid-based protein binding reagents that are specific for their cognate protein; and offers proprietary SomaScan services, which provide multiplex protein detection and quantification of protein levels in complex biological samples. The company's SOMAmers/SomaScan technology enables researchers to analyze various types of biological samples for protein biomarker signatures, which can be utilized in drug discovery and development. Its SomaScan's biomarker discoveries help in diagnostic applications in various areas of diseases, including cardiovascular and metabolic disease, nonalcoholic steatohepatitis, wellness, and others. The company also provides SomaSignal research use only and laboratory-developed tests. It serves research and clinical customers with a focus on pharmaceutical and biotechnology companies, and academic research institutions, as well as facilitates drug development, analysis of clinical trials, and new human biology insights by assessing protein-protein and protein-gene networks.
Everything we know about the Intchains Group IPO, plus information on how to buy in.
Everything we know about the Biostage IPO, plus information on how to buy in.
Everything we know about the Wang & Lee Group IPO, plus information on how to buy in.
Everything we know about the OptMed IPO, plus information on how to buy in.
Everything we know about the Lichen China IPO, plus information on how to buy in.
Everything we know about the LeeWay Services IPO, plus information on how to buy in.
Everything we know about the Nano Labs IPO, plus information on how to buy in.
Everything we know about the Warrantee IPO, plus information on how to buy in.
Everything we know about the Treasure Global IPO, plus information on how to buy in.
Everything we know about the BIOLIFE4D IPO, plus information on how to buy in.